The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy
Nature Medicine2017Vol. 23(12), pp. 1436–1443
Citations Over TimeTop 10% of 2017 papers
Naoki Hosen, Yukiko Matsunaga, Kana Hasegawa, Hiroshi Matsuno, Yuki Nakamura, Mio Makita, Kouki Watanabe, Mikako Yoshida, Kei Satoh, Soyoko Morimoto, Fumihiro Fujiki, Hiroko Nakajima, Jun Nakata, Sumiyuki Nishida, Akihiro Tsuboi, Yoshitaka Oka, Masahiro Manabe, Hiroyoshi Ichihara, Yasutaka Aoyama, Atsuko Mugitani, Takafumi Nakao, Masayuki Hino, Ryosuke Uchibori, Keiya Ozawa, Yoshihiro Baba, Seitaro Terakura, Naoki Wada, Eiichi Morii, Junichi Nishimura, Kiyoshi Takeda, Yusuke Oji, Haruo Sugiyama, Junichi Takagi, Atsushi Kumanogoh
Related Papers
- → B7-H3/CD276: An Emerging Cancer Immunotherapy(2021)282 cited
- → Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators(2020)80 cited
- → CAR-T Immunotherapy to Beat Solid Tumors: From Challenges to Improvements(2022)2 cited
- → The present situation and prospect of CAR-T cellular immunotherapy(2020)
- → Current status and problems of chimeric antigen receptor T cell immunotherapy in treatment of hematological malignancies(2020)